Marie Evangelista

Sunesis (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index10.3kcitations167works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(38), Cancer-related Molecular Pathways(25), DNA Repair Mechanisms(19), Epigenetics and DNA Methylation(19), Cancer Genomics and Diagnostics(19)

Publications167 total

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers
Journal of Medicinal Chemistry·2026Open Access
Abstract A027: First-in-class oral macrocyclic Cyclin D1-selective inhibitors demonstrate anti-tumor activity in Cyclin D1-dependent tumors
Molecular Cancer Therapeutics·2025
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
Nature·2025· 9 citedOpen Access
Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity
Journal of Medicinal Chemistry·2025· 4 cited
Abstract LB296: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/Chk1 DNA repair pathway
Cancer Research·2025
Abstract 7133: Phenomics-enabled discovery and optimization of small-molecule RBM39 degraders as an alternative to CDK12 targeting in high-grade serous ovarian cancer (HGSOC)
Cancer Research·2024
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors
ACS Medicinal Chemistry Letters·2023· 6 citedOpen Access
AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues
Journal of Proteome Research·2023· 9 citedOpen Access
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Nature Cancer·2023· 170 citedOpen Access
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
BMC Cancer·2023· 21 citedOpen Access
Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets
Cancer Research·2023· 1 cited
Supplementary Figure 3 from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplementary Figure and Table Legend from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplementary Figure 2 from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplementary Figure 2 from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplementary Figures S1-S5 from AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
2023Open Access
Supplementary Table 2 from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplementary Table 3 from Identification of Preferred Chemotherapeutics for Combining with a <i>CHK1</i> Inhibitor
2023Open Access
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Charles Boone(13), David Peterson(7), Thomas O’Brien(7), Frédéric J. de Sauvage(7), Georgia Hatzivassiliou(6), Rana Mroue(5), Deepak Sampath(5), Mark Merchant(5), Hans E. Purkey(5), Shiva Malek(5), Benjamin Haley(5), Sally H. Zigmond(4), Anneleen Daemen(4), Rebecca Hong(4), Laura Corson(4), Amy H.Y. Tong(3), Gary D. Bader(3), Changsong Yang(3), Aaron Boudreau(3), Jeff Settleman(3)